SFI
AIM

Susquehanna Fundamental Investments’s AIM ImmunoTech AIM Stock Holding History

Susquehanna Fundamental Investments’s Portfolio AIM Stock Details AIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-170
Closed -$39K – 1858
2021
Q1 		$39K Sell
170
-32
-16% -$7.22K ﹤0.01% 1505
2020
Q4 		$36K Buy
202
+86
+74% +$17.2K ﹤0.01% 1461
2020
Q3 		$25K Hold
116
– – ﹤0.01% 1343
2020
Q2 		$29K Buy
+116
New +$28.2K ﹤0.01% 954

Other funds holding AIM

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Susquehanna Fundamental Investments's AIM Position: Q2 2021 in Review

Susquehanna Fundamental Investments sold out of AIM ImmunoTech (AIM) in Q2 2021, closing a stake of 170 shares — an estimated $39K sold.

Susquehanna Fundamental Investments first reported a position in AIM in Q2 2020 and held it in 4 quarters. The position peaked at $39K in Q1 2021. 35 funds tracked by Wall St. Rank hold AIM as of Q2 2021.

  • Susquehanna Fundamental Investments reported no remaining AIM ImmunoTech position as of Q2 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 170 AIM ImmunoTech shares in Q2 2021, an estimated $39K.
  • Susquehanna Fundamental Investments first reported a position in AIM ImmunoTech in Q2 2020 and held it in 4 quarters.
  • Susquehanna Fundamental Investments's AIM ImmunoTech position peaked at $39K in Q1 2021.
  • 35 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q2 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q2 2021, filed 11 Aug 2021.